Samuel Limat

1.8k total citations
91 papers, 1.3k citations indexed

About

Samuel Limat is a scholar working on Oncology, Geriatrics and Gerontology and Economics and Econometrics. According to data from OpenAlex, Samuel Limat has authored 91 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 18 papers in Geriatrics and Gerontology and 16 papers in Economics and Econometrics. Recurrent topics in Samuel Limat's work include Pharmaceutical Practices and Patient Outcomes (18 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Cancer Treatment and Pharmacology (11 papers). Samuel Limat is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (18 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Cancer Treatment and Pharmacology (11 papers). Samuel Limat collaborates with scholars based in France, United States and Switzerland. Samuel Limat's co-authors include Virginie Nerich, Éric Deconinck, Edgar Tissot, M.‐C. Woronoff‐Lemsi, Micheline Jacquet, C. Cornette, Marie-Christine Woronoff-Lemsi, Xavier Pivot, Gilles Capellier and J.L. Dupond and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Annals of Oncology.

In The Last Decade

Samuel Limat

86 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Samuel Limat France 20 292 247 199 178 160 91 1.3k
Catherine Rioufol France 17 246 0.8× 245 1.0× 148 0.7× 50 0.3× 63 0.4× 89 969
Virginie Nerich France 20 334 1.1× 110 0.4× 49 0.2× 221 1.2× 194 1.2× 83 1.2k
Sue Kirsa Australia 18 175 0.6× 175 0.7× 67 0.3× 115 0.6× 36 0.2× 44 695
Florence Ranchon France 16 195 0.7× 236 1.0× 146 0.7× 45 0.3× 31 0.2× 58 812
Elise H. Lawson United States 22 313 1.1× 69 0.3× 92 0.5× 255 1.4× 259 1.6× 52 2.0k
Aurélien Vesin France 31 326 1.1× 75 0.3× 330 1.7× 789 4.4× 872 5.5× 55 3.2k
Olivier Moranne France 29 85 0.3× 78 0.3× 197 1.0× 280 1.6× 504 3.1× 143 3.0k
Kamal Sud Australia 26 151 0.5× 36 0.1× 367 1.8× 381 2.1× 340 2.1× 143 2.6k
Ju‐Yeun Lee South Korea 17 123 0.4× 280 1.1× 44 0.2× 107 0.6× 57 0.4× 135 1.2k
F Borst Switzerland 21 177 0.6× 26 0.1× 44 0.2× 207 1.2× 208 1.3× 53 1.5k

Countries citing papers authored by Samuel Limat

Since Specialization
Citations

This map shows the geographic impact of Samuel Limat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Limat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Limat more than expected).

Fields of papers citing papers by Samuel Limat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Limat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Limat. The network helps show where Samuel Limat may publish in the future.

Co-authorship network of co-authors of Samuel Limat

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Limat. A scholar is included among the top collaborators of Samuel Limat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Limat. Samuel Limat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sadeghipour, Farshid, et al.. (2025). Carbon footprint of a chemotherapy production unit within a hospital pharmacy: Time for green pharmacy. Journal of Oncology Pharmacy Practice. 3222351913–3222351913. 3 indexed citations
2.
Oudard, Stéphane, Gwénaëlle Gravis, F. Kleinclauss, et al.. (2021). Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. Clinical Genitourinary Cancer. 19(5). e326–e333. 11 indexed citations
3.
Daguindau, Étienne, Cyril Faure, Marie Kroemer, et al.. (2021). Oral therapy adherence and satisfaction in patients with multiple myeloma. Annals of Hematology. 100(7). 1803–1813. 5 indexed citations
4.
Louvrier, Aurélien, Sarah Fischer, Samuel Limat, et al.. (2021). ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature. Frontiers in Medicine. 8. 713047–713047. 6 indexed citations
5.
Kroemer, Marie, Célia Turco, Laurie Spehner, et al.. (2020). Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases. Journal for ImmunoTherapy of Cancer. 8(2). e001478–e001478. 31 indexed citations
6.
Kapel, Nathalie, Frédéric Grenouillet, Stéphane Koch, et al.. (2020). A systematic review of economic evaluation in fecal microbiota transplantation. Infection Control and Hospital Epidemiology. 41(4). 458–466. 8 indexed citations
7.
Curtit, Elsa, et al.. (2019). Interaction between phytotherapy and oral anticancer agents: prospective study and literature review. Medical Oncology. 36(5). 45–45. 49 indexed citations
8.
Fagnoni, Philippe, Angélique Vienot, Christophe Borg, et al.. (2017). A systematic review of economic evaluation in pancreatic ductal adenocarcinoma. European Journal of Cancer. 86. 207–216. 12 indexed citations
9.
Philippe, Laure, Sabeha Biichlé, Sophie Perrin, et al.. (2017). Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica. 102(11). 1861–1868. 36 indexed citations
10.
Pivot, Xavier, G. Aulagner, Jean‐Yves Blay, et al.. (2015). Challenges in the implementation of trastuzumab biosimilars. Anti-Cancer Drugs. 26(10). 1009–1016. 11 indexed citations
11.
Nerich, Virginie, Elsa Curtit, Fernando Bazán, et al.. (2014). Évaluation économique de l’utilisation en routine du test Oncotype DX® dans la prise en charge des cancers du sein en Franche-Comté. Bulletin du Cancer. 101(7-8). 681–689. 6 indexed citations
12.
Desmettre, T., et al.. (2011). Analysis of 379 drug prescriptions at a call Center 15. HAL (Le Centre pour la Communication Scientifique Directe).
13.
Fagnoni, Philippe, Nöel Milpied, Samuel Limat, et al.. (2009). Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma. HAL (Le Centre pour la Communication Scientifique Directe). 1 indexed citations
14.
Rossano, Alexandra, et al.. (2007). Antimicrobial resistance profile of Actinobacillus pleuropneumoniae and Actinobacillus porcitonsillarum. Veterinary Microbiology. 122(1-2). 146–156. 55 indexed citations
15.
Chaigneau, L., et al.. (2006). Computerized prescribing of standardized chemotherapy schedules: residual medication errors and pharmaceutical interventions.. Journal de Pharmacie Clinique. 25(1). 33–38. 5 indexed citations
16.
Limat, Samuel, et al.. (2006). Prescription informatisée et protocolisée des chimiothérapies : risque iatrogène résiduel et interventions pharmaceutiques. Journal de Pharmacie Clinique. 25(1). 33–38. 6 indexed citations
17.
Limat, Samuel, et al.. (2004). From Randomised Clinical Trials to Clinical Practice. PharmacoEconomics. 22(10). 633–641. 12 indexed citations
18.
Legat, Christoph, et al.. (2003). Economic impact of centralized preparation of cytotoxic drugs. Journal de Pharmacie Clinique. 22(4). 181–185. 1 indexed citations
19.
Limat, Samuel, et al.. (2003). Impact économique de la préparation centralisée des médicaments anticancéreux. Journal de Pharmacie Clinique. 22(4). 181–185. 11 indexed citations
20.
Limat, Samuel, Laurent Voillat, Yvette Bernard, et al.. (2003). Early cardiotoxicity of the CHOP regimen in aggressivenon-Hodgkin’s lymphoma. Annals of Oncology. 14(2). 277–281. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Rioufol Breakdown of academic impact, for papers by Virginie Nerich Breakdown of academic impact, for papers by Sue Kirsa Breakdown of academic impact, for papers by Florence Ranchon Breakdown of academic impact, for papers by Elise H. Lawson Breakdown of academic impact, for papers by Aurélien Vesin Breakdown of academic impact, for papers by Olivier Moranne Breakdown of academic impact, for papers by Kamal Sud Breakdown of academic impact, for papers by Ju‐Yeun Lee Breakdown of academic impact, for papers by F Borst
Rankless by CCL
2026